Login to Your Account

Clinic Roundup

Thursday, November 3, 2011

• Isis Pharmaceuticals Inc., of Carlsbad, Calif., said it started Phase I studies of ISIS-GCGRRx and ISIS-GCCRRx, antisense drugs in development for Type II diabetes.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription